Skip to search formSkip to main contentSkip to account menu

ixazomib citrate

Known as: 1,3,2-dioxaborinane-4-acetic acid, 4-carboxy-2-((1r)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-6-oxo- 
The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

MLN 9708
Positive Regulation of ApoptosisProteasome Function InhibitionSignal Transduction Inhibitionixazomib 4 MG Oral Capsule [Ninlaro]

Broader (1)

ixazomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
True molecular structure of ixazomib citrate
Ixazomib citrate is a very recently approved anti-cancer drug. In all currently available literature, the molecule is… 
Review
2015
Review
2015
THE NEW NONINVASIVE OPTION FOR AVERAGE-RISK PATIENTS WHO AVOID COLONOSCOPY
s). 2012;120: Abstract 74. 4. Offidani M, Corvatta L, Caraffa P, et al. An evidence-based review of ixazomib citrate and its… 
2014
2014
Integrated nonclinical and clinical risk assessment to obviate the need for a dedicated QTc study of ixazomib citrate (MLN9708) in cancer patients (pts).
2553 Background: Ixazomib citrate is an investigational oral proteasome inhibitor in phase 3 (P3) clinical development. It is… 
2014
2014
Cancer Therapy : Preclinical Preclinical Activity of theOral Proteasome InhibitorMLN 9708 in Myeloma Bone Disease
Purpose: MLN9708 (ixazomib citrate), which hydrolyzes to pharmacologically active MLN2238 (ixazomib), is a next-generation… 
2014
2014
Ixazomib Citrate (MLN9708) Inhibits Kidney Allograft Infiltrating Macrophages in a CNI Minimizing Strategy.: Abstract# D2680
2013
2013
Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
MLN9708 (ixazomib citrate) is an investigational, orally bioavailable proteasome inhibitor that is under development by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)